Humoral and cellular immunity of two‐dose inactivated COVID‐19 vaccination in Chinese children: A prospective cohort study
暂无分享,去创建一个
Yufei Wang | Tangchun Wu | Chaolong Wang | Xi Wang | Qi Wang | An Pan | Li Liu | Qian Liu | Yingying Zhao | Xionglin Fan | Haoyang Cai | R. Gong | Pinpin Long | Hao Wang | Yu Yuan | Jun Xu | Li Chen | Jing Yi | Yandi Zhang | Dong-Sheng Di | T. Yuan | Yanshou Lei | Zhen Wang | Yuying Wen | Wenhui Li | Qinli Chen | B. Wu | T. Zhou | M. Gan | R. Zeng | Jia Li | Jinge Cao | S. Peng | Jin-bao Lei | Xuemei Song | P. Long | Xuemei Song | Bihao Wu
[1] Xinjie Li,et al. Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study , 2022, Journal of Infection.
[2] A. Pollard,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial , 2022, The Lancet.
[3] E. Undurraga,et al. Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile , 2022, Nature Medicine.
[4] E. Wherry,et al. Understanding T cell responses to COVID-19 is essential for informing public health strategies , 2022, Science Immunology.
[5] D. Weiskopf,et al. An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile , 2022, medRxiv.
[6] P. Moss. The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.
[7] Xiangxi Wang,et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants , 2022, Nature.
[8] Jian K. Liu,et al. Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma , 2022, Emerging microbes & infections.
[9] D. Greenberg,et al. The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases , 2022, Vaccines.
[10] A. Walls,et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement , 2021, bioRxiv.
[11] Xionglin Fan,et al. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines , 2021, Frontiers in Immunology.
[12] A. Sette,et al. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine , 2021, Frontiers in Immunology.
[13] S. Mallapaty. China’s COVID vaccines have been crucial — now immunity is waning , 2021, Nature.
[14] Xiaomin Yan,et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine , 2021, Clinical Microbiology and Infection.
[15] S. Peng,et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine , 2021, Cell Discovery.
[16] A. Wilder-Smith,et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine , 2021, The New England journal of medicine.
[17] W. Wang,et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial , 2021, The Lancet Infectious Diseases.
[18] H. Hou,et al. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection , 2021, Journal of Allergy and Clinical Immunology.
[19] E. Wherry,et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination , 2021, Immunity.
[20] M. Beltramello,et al. Broad sarbecovirus neutralization by a human monoclonal antibody , 2021, Nature.
[21] Yu Li,et al. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients , 2021, Cellular & Molecular Immunology.
[22] M. Beltramello,et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.
[23] O. Ohara,et al. Influenza virus infection expands the breadth of antibody responses through IL-4 signalling in B cells , 2021, Nature Communications.
[24] Tangchun Wu,et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection , 2021, Cellular & Molecular Immunology.
[25] Changgui Li,et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial , 2021, The Lancet Infectious Diseases.
[26] E. Lau,et al. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection , 2021, medRxiv.
[27] D. Fremont,et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization , 2021, Cell Host & Microbe.
[28] L. Fang,et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study , 2021, The Lancet Infectious Diseases.
[29] Xing Wu,et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine , 2021, Emerging microbes & infections.
[30] J. Bloom,et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2020, bioRxiv.
[31] M. McElrath,et al. COVID-19 and the Path to Immunity. , 2020, JAMA.
[32] Y. Wen,et al. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China , 2020, JAMA internal medicine.
[33] Yongli Yang,et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. , 2020, JAMA.
[34] U. Reimer,et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.
[35] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[36] P. Kremsner,et al. Herd immunity and vaccination of children for COVID-19 , 2020, International Journal of Infectious Diseases.
[37] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[38] Vineet D. Menachery,et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients , 2020, Cell Reports Medicine.
[39] D. Booth,et al. HBV vaccination and HBV infection induces HBV-specific natural killer cell memory , 2020, Gut.
[40] F. Krammer. The human antibody response to influenza A virus infection and vaccination , 2019, Nature Reviews Immunology.
[41] K. Meyer zum Büschenfelde,et al. Kinetics of hepatitis B surface antigen–specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of the in vitro antibody response by interferon gamma , 1999, Hepatology.